NASDAQ:CELZ Creative Medical Technology (CELZ) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free CELZ Stock Alerts $4.42 -0.39 (-8.11%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.35▼$4.8050-Day Range$4.03▼$6.4552-Week Range$3.93▼$10.28Volume21,477 shsAverage Volume165,040 shsMarket Capitalization$6.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Creative Medical Technology alerts: Email Address Creative Medical Technology MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.68) to ($3.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.78 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Creative Medical Technology. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.76% of the float of Creative Medical Technology has been sold short.Short Interest Ratio / Days to CoverCreative Medical Technology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Creative Medical Technology has recently decreased by 19.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCreative Medical Technology does not currently pay a dividend.Dividend GrowthCreative Medical Technology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELZ. Previous Next 1.9 News and Social Media Coverage News SentimentCreative Medical Technology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Creative Medical Technology this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Creative Medical Technology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Creative Medical Technology is held by insiders.Percentage Held by InstitutionsOnly 1.42% of the stock of Creative Medical Technology is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Creative Medical Technology are expected to grow in the coming year, from ($4.68) to ($3.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Creative Medical Technology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Creative Medical Technology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCreative Medical Technology has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Creative Medical Technology Stock (NASDAQ:CELZ)Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Read More CELZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELZ Stock News HeadlinesApril 24, 2024 | morningstar.comCreative Medical Technology Holdings Inc CELZApril 19, 2024 | americanbankingnews.comComparing Zura Bio (NASDAQ:ZURA) & Creative Medical Technology (NASDAQ:CELZ)April 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. March 24, 2024 | finance.yahoo.comCreative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 18, 2024 | forbes.comMedical Practices And Branding In A Digital AgeMarch 18, 2024 | theglobeandmail.comCreative Medical Technology Skyrockets on Word of New Diabetes MedicationMarch 7, 2024 | msn.comWhy Is Diabetes Focused Creative Medical Stock Surging On Thursday?March 7, 2024 | markets.businessinsider.comCreative Medical Announces FDA Authorization For Expanded Access For CELZ-201; Stock UpApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. March 7, 2024 | marketwatch.comCreative Medical Shares Rise 37% After FDA Authorization for CELZ-201March 7, 2024 | msn.comCreative Medical stock rallies for second day on FDA updatesMarch 7, 2024 | finance.yahoo.comCreative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded AccessMarch 6, 2024 | morningstar.comCreative Medical Technology Holdings IncMarch 6, 2024 | markets.businessinsider.comCreative Medical Receives FDA Orphan Drug Designation For CELZ-101; Stock Up In Pre-marketMarch 6, 2024 | marketwatch.comCreative Medical Shares Rally Premarket on FDA Orphan DesignationMarch 6, 2024 | msn.comCreative Medical stock rallies 18% on FDA orphan drug designationMarch 6, 2024 | businesswire.comCreative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation TherapyFebruary 15, 2024 | investing.comCreative Medical Technology Holdings Inc (CELZ)February 9, 2024 | benzinga.comSteven L White's Net WorthDecember 20, 2023 | finance.yahoo.comCreative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back PainOctober 11, 2023 | msn.comCreative Medical to initiate trial of lower back pain treatmentOctober 10, 2023 | markets.businessinsider.comCreative Medical Gets IRB Approval For StemSpine Trial Using AlloStem Cell TherapyOctober 10, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back PainSeptember 22, 2023 | finance.yahoo.comWhat Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy StockSeptember 19, 2023 | finance.yahoo.comCreative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back PainAugust 24, 2023 | finance.yahoo.comWhat Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?August 23, 2023 | benzinga.comWhat Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?See More Headlines Receive CELZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CELZ CUSIPN/A CIK1187953 Webwww.creativemedicaltechnology.com Phone(833) 336-7636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,290,000.00 Net MarginsN/A Pretax Margin-58,744.45% Return on Equity-41.48% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio27.68 Quick Ratio27.67 Sales & Book Value Annual Sales$10,000.00 Price / Sales601.12 Cash FlowN/A Price / Cash FlowN/A Book Value$7.48 per share Price / Book0.59Miscellaneous Outstanding Shares1,360,000Free Float1,312,000Market Cap$6.01 million OptionableNot Optionable Beta2.21 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Timothy Warbington (Age 62)Co-Founder, Chairman, President & CEO Comp: $429kMr. Donald Dickerson (Age 59)Senior VP, CFO & Director Comp: $390kKey CompetitorsTitan PharmaceuticalsNASDAQ:TTNPChromocell TherapeuticsNYSE:CHROFresh Tracks TherapeuticsNASDAQ:FRTXGamida CellNASDAQ:GMDATRACON PharmaceuticalsNASDAQ:TCONView All CompetitorsInsiders & InstitutionsAaron Wealth Advisors LLCBought 16,400 shares on 4/25/2024Ownership: 1.206%Timothy WarbingtonBought 800 shares on 6/27/2023Total: $3,552.00 ($4.44/share)View All Insider TransactionsView All Institutional Transactions CELZ Stock Analysis - Frequently Asked Questions How have CELZ shares performed in 2024? Creative Medical Technology's stock was trading at $4.61 at the start of the year. Since then, CELZ stock has decreased by 4.1% and is now trading at $4.42. View the best growth stocks for 2024 here. Are investors shorting Creative Medical Technology? Creative Medical Technology saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 23,200 shares, a decline of 19.2% from the March 31st total of 28,700 shares. Based on an average trading volume of 201,700 shares, the short-interest ratio is currently 0.1 days. Approximately 1.8% of the company's stock are sold short. View Creative Medical Technology's Short Interest. When is Creative Medical Technology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CELZ earnings forecast. How were Creative Medical Technology's earnings last quarter? Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) released its quarterly earnings data on Friday, March, 22nd. The company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.08. When did Creative Medical Technology's stock split? Creative Medical Technology's stock reverse split on the morning of Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Creative Medical Technology's major shareholders? Creative Medical Technology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Aaron Wealth Advisors LLC (1.21%). Insiders that own company stock include Michael H Finger and Timothy Warbington. View institutional ownership trends. How do I buy shares of Creative Medical Technology? Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELZ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
